Efficiency of C-reactive protein in prognosis evaluation of prostate cancer: a systematic review and meta-analysis

Background: Tumor markers can be diagnostically suggestive and are sometimes even related to prognostic prediction certain diseases. Multiple studies have shown the effectiveness in the prediction of prostate cancer (PCa) by the use of C-reactive protein (CRP). This meta-analysis was conducted to facilitate a conclusion regarding the values of CRP in the prediction of survival rate in patients with PCa. Methods: Manuscripts were searched, identified, and collected from different databases; quality evaluation was performed according to the different search strategies involved. Information including the comparison between overall survival (OS) and cancer-specific survival (CSS) rate were retained from different studies in patients with evaluated or lowered CRP levels. Progression-free survival (PFS) was also recorded in relation to the log of CRP. Level of relevance was assessed using hazard ratio (I IR) and 95% confidence interval (CI). Heterogenicity testing was performed by using Cochran's Q test and Higgins I-2 statistics. When P value <0.05, the outcome was considered statistically significant. Results: A total 12 of manuscripts were included and evaluated from the 1,523 initially identified studies. The results of OS and PFS were 1.57 (95% CI: 1.34 to 1.85) and 1.50 (95% CI: 1.25 to 1.81), respectively. For CSS, the combined HR and 95% CI was 1.92 (95% CI: 1.36 to 2.70), which revealed a significant correlation between increased level of CRP and CSS in PCa patients. Conclusions: This meta-analysis revealed that CRP value could be one of the critical indicators to predict the survival rate of PCa patients.

Automated summary

This meta-analysis focused on the value of C-reactive protein (CRP) in predicting survival rate in patients with prostate cancer (PCa). Results from 12 included studies showed a significant correlation between increased CRP levels and survival rate among PCa patients.